Institutional Investors Love Kindred Biosciences Inc (NASDAQ:KIN)

Kindred Biosciences, Inc. (NASDAQ:KIN) Logo

Sentiment for Kindred Biosciences Inc (NASDAQ:KIN)

Kindred Biosciences Inc (NASDAQ:KIN) institutional sentiment increased to 2 in Q2 2018. Its up 1.22, from 0.78 in 2018Q1. The ratio has improved, as 38 active investment managers increased or opened new stock positions, while 19 sold and reduced their stakes in Kindred Biosciences Inc. The active investment managers in our partner’s database now possess: 19.86 million shares, up from 16.83 million shares in 2018Q1. Also, the number of active investment managers holding Kindred Biosciences Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 16 Increased: 23 New Position: 15.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $412.39 million. The companyÂ’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

The stock decreased 3.11% or $0.39 during the last trading session, reaching $12.16. About 89,706 shares traded. Kindred Biosciences, Inc. (NASDAQ:KIN) has risen 85.33% since December 8, 2017 and is uptrending. It has outperformed by 69.71% the S&P500.

Analysts await Kindred Biosciences, Inc. (NASDAQ:KIN) to report earnings on March, 7. They expect $-0.42 EPS, down 20.00 % or $0.07 from last year’s $-0.35 per share. After $-0.39 actual EPS reported by Kindred Biosciences, Inc. for the previous quarter, Wall Street now forecasts 7.69 % negative EPS growth.

Park West Asset Management Llc holds 2.38% of its portfolio in Kindred Biosciences, Inc. for 6.00 million shares. General American Investors Co Inc owns 594,878 shares or 0.58% of their US portfolio. Moreover, Ariel Investments Llc has 0.27% invested in the company for 2.22 million shares. The Massachusetts-based Granahan Investment Management Inc Ma has invested 0.2% in the stock. Eam Investors Llc, a California-based fund reported 63,883 shares.

Since January 1, 0001, it had 1 insider purchase, and 5 sales for $5.87 million activity.

Kindred Biosciences, Inc. (NASDAQ:KIN) Ratings Coverage

Ratings analysis reveals 80% of Kindred Biosciences’s analysts are positive. Out of 5 Wall Street analysts rating Kindred Biosciences, 4 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $1200 while the high is $30. The stock’s average target of $20.75 is 70.64% above today’s ($12.16) share price. KIN was included in 6 notes of analysts from June 26, 2018. The stock of Kindred Biosciences, Inc. (NASDAQ:KIN) has “Neutral” rating given on Tuesday, August 7 by Ladenburg Thalmann. The company was maintained on Tuesday, June 26 by H.C. Wainwright. The rating was maintained by Cantor Fitzgerald with “Overweight” on Wednesday, October 31. The stock of Kindred Biosciences, Inc. (NASDAQ:KIN) earned “Buy” rating by FBR Capital on Tuesday, August 7.

More notable recent Kindred Biosciences, Inc. (NASDAQ:KIN) news were published by: Globenewswire.com which released: “Acquisition of shares in Radisson Hospitality AB completed – GlobeNewswire” on November 13, 2018, also Seekingalpha.com with their article: “Kindred Bio up 22% premarket on positive KIND-016 data – Seeking Alpha” published on October 31, 2018, Nasdaq.com published: “Siyata Mobile to Attend and Present at LD Micro Annual Main Event – Nasdaq” on November 21, 2018. More interesting news about Kindred Biosciences, Inc. (NASDAQ:KIN) were released by: Nasdaq.com and their article: “Quadron CEO Wins First Ever “Woman in Weed – Trailblazer” Award at Fifth Annual Canadian Cannabis Awards – Nasdaq” published on December 03, 2018 as well as Nasdaq.com‘s news article titled: “Crypto Startup Reels in Twitch Executive to Spearhead Adoption Strategies – Nasdaq” with publication date: September 18, 2018.

Kindred Biosciences, Inc. (NASDAQ:KIN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.